Generic Name: triheptanoin
Brand Name: Dojolvi
Manufacturer: Ultragenyx Canada Inc
Therapeutic Area: Long-chain fatty acid oxidation disorders
Indications: Dojolvi (triheptanoin) is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).
Manufacturer Requested Reimbursement Criteria1: Ultragenyx is requesting triheptanoin be reimbursed for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD)
Submission Type: Initial
NOC Status at Filing: Post NOC
Project Status: Received
Companion Diagnostics: No
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient/clinician input open||February 26, 2021|
|Call for patient/clinician input closed||April 23, 2021|
|Submission received||March 31, 2021|